---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-050227"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:51:39.750075+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allogene Therapeutics Reports Q3 2025 Net Loss of $41.4M, Cash of $277.1M

## Summary
- Q3 2025 net loss $41.4M ($0.19 per share), cash $277.1M, cash runway into 2H 2027.
- Phase 2 ALPHA3 trial for cema-cel in LBCL on track for futility analysis in 1H 2026.
- Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease enrolling, proof-of-concept data expected 1H 2026.
- Phase 1 TRAVERSE trial for ALLO-316 in RCC shows durable responses; next phase under evaluation.
- Additional ALPHA3 trial sites in Australia and South Korea expected to open early 2026.

## SEC filing metadata
- accession: 0001628280-25-050227
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000162828025050227/0001628280-25-050227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000162828025050227/allo-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-050227
- JSON: https://secwatch.observer/filing/0001628280-25-050227.json
- Plain text: https://secwatch.observer/filing/0001628280-25-050227.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.